Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended August 31, 2008 (First quarter of fiscal 2009)
Business Overview: Biomerica develops and markets diagnostic products, primarily the EZ Detect product line. The company operates globally with significant sales in Europe and Asia.
Key Financial Metrics
| Metric | Q1 FY2009 (Ended Aug 31, 2008) |
Q1 FY2008 (Ended Aug 31, 2007) |
|---|---|---|
| Net Sales | $1,194,345 | $1,340,065 |
| Gross Profit | $533,129 | $604,444 |
| Gross Margin | 44.6% | 45.1% |
| Operating Income | $147,258 | $214,417 |
| Net Income | $140,812 | $885,386 |
| Diluted EPS | $0.02 | $0.13 |
| Cash from Operations | $49,595 | $477,616 |
| Cash & Equivalents (End of Period) | $1,960,826 | $990,559 |
| Working Capital | $3,568,227 | N/A |
| Total Debt (Current + Long Term) | $154,722 | N/A |
Note: Total debt includes $53,201 in current portions of loans/leases and $101,521 in long-term equipment loans. The shareholder loan was paid off during the quarter.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by 10.9% ($145,720) compared to the prior year. Management attributes this primarily to reduced screening programs by certain drug stores, impacting EZ Detect sales.
- Profitability Drop: Net income fell significantly to $140,812 from $885,386. This sharp decline is largely due to the absence of a one-time gain of approximately $697,000 in the prior year from the sale of a marketable security carried at zero value.
- Expense Management: Research and Development (R&D) expenses decreased by 32.6% ($22,756) due to reduced personnel and material costs. Conversely, Selling, General, and Administrative (SG&A) expenses increased by 5.8% ($18,600), driven by higher wages and SOX 404 compliance costs.
- Cash Flow: Operating cash flow decreased to $49,595 from $477,616. The reduction is attributed to the lack of the prior year's one-time gain and an increase in inventory levels of approximately $209,515.
Outlook, Risks, and Management Commentary
- Outlook: Management expects R&D costs to increase in the second quarter as work on specific research projects intensifies. No specific revenue guidance was provided for the full fiscal year.
- Liquidity: The company maintains a strong liquidity position with working capital of $3.57 million. A $200,000 working capital line of credit was extended to November 1, 2008, with no outstanding balance as of August 31, 2008.
- Debt Repayment: The company paid off a shareholder note of $95,936 during the quarter.
- International Expansion: In June 2008, the company incorporated a subsidiary in Mexico ("Biomerica de Mexico") to establish a future maquiladora operation.
- Risks: Key risks include dependence on international distributors, potential raw material shortages, regulatory delays, and competition from larger entities. The company also notes susceptibility to macroeconomic downturns and border shutdowns.
Investor Verification Checklist
- Revenue Drivers: Verify the status of drug store screening programs and the demand outlook for the EZ Detect product line.
- Inventory Levels: Review the $1.95 million inventory balance against sales forecasts to assess obsolescence risk, particularly given the $209k increase in inventory during the quarter.
- One-Time Items: Confirm that the prior year's $697k gain was indeed non-recurring and does not distort year-over-year comparisons.
- Debt Covenants: Review the terms of the $200,000 line of credit and equipment loan to ensure compliance with covenants, especially given the collateralization of substantially all assets.
- Geographic Concentration: Assess the impact of economic conditions in Europe (57% of sales) and Asia (23% of sales) on future revenue stability.